Of the six SCC lines studied, CCK168 is most sensitive to combinatorial immunotherapy but, even in this line, tumor responses are heterogeneous and only 60% of tumors achieve CR following α-PD-1/α-TGFβ combination therapy at the doses used. This evidence concerns the gene TGFB1 and neoplasm.